618 filings
Page 5 of 31
S-8
dklvy3e q16hh
26 Aug 22
Registration of securities for employees
5:01pm
8-K
4x01145wx6ri2zroqe5y
26 Aug 22
Termination of a Material Definitive Agreement
4:39pm
8-K
wb3r9s8xn99f
8 Aug 22
VBI Vaccines Reports Second Quarter 2022 Financial Results and Provides Corporate Update
8:01am
8-K
s24km4f7
12 Jul 22
VBI Vaccines Announces Appointment of John Dillman as Chief Commercial Officer
8:00am
8-K
pbbj0p7w7r
1 Jul 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:15pm
8-K
nfbexz21941io48pbps3
28 Jun 22
VBI Vaccines Announces New Long-Term Follow-Up Clinical Data for its 3-Antigen Adult Hepatitis B Vaccine Presented at EASL 2022
8:00am
8-K
z9qafjp2k65vfn
22 Jun 22
VBI Vaccines Announces Results of Annual General Meeting
6:48pm
8-K
amhtr92 3s
22 Jun 22
VBI Vaccines Receives U.S. FDA Orphan Drug Designation for VBI-1901 for the Treatment of Glioblastoma
8:00am
8-K
iz94xw8
6 Jun 22
VBI Vaccines Presents Updated Phase 2a Tumor Response and Overall Survival Data for VBI-1901 in Recurrent GBM at the 2022 ASCO Annual Meeting
8:00am
8-K
h1k6xfe9
1 Jun 22
VBI Vaccines Announces UK MHRA Marketing Authorisation for PreHevbri™, a 3-Antigen
8:00am
8-K
75b4ge5dwx 93oz6yv
19 May 22
Regulation FD Disclosure
8:00am
8-K
1j3i83r6vm 7d
9 May 22
VBI Vaccines Reports First Quarter 2022 Financial Results and Provides Corporate Update
8:00am
8-K
0hhhgv
2 May 22
VBI Vaccines Announces European Commission Marketing Authorisation for PreHevbri™, a 3-Antigen Adult Hepatitis B Vaccine
8:00am
DEFA14A
970zs7ksq0fy7bj cao
29 Apr 22
Additional proxy soliciting materials
4:55pm
8-K
vxanjksc6q
5 Apr 22
VBI Vaccines Announces New Data and Progress of VBI-2900, VBI’s eVLP Coronavirus Program
8:00am